slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 69,571-69,600
Pages 3,679
Rows per page 30
Component
69,571-69,600 of 110,355
22
Slide 22 of a presentation deck.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
25
Includes a stacked bar chart showing revenue trends by product over 7 quarters.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
26
Includes a stacked bar chart for Soliris registry data and a trial design schematic for gefurulimab.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
27
Includes a biological pathway diagram and a table of drug assets.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations Beat · Visualization1 hit
33
Includes progress against specific 2025/2026 targets.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations 1 hit
37
Data presented in stacked bar charts with corresponding data tables below each chart.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations 1 hit
38
CER = constant exchange rates; EM = Emerging Markets; ERoW = Established Rest of World.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations 1 hit
39
Data presented as stacked bar charts with corresponding data tables below each chart.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations 1 hit
41
Data reflects post-acquisition reporting for Alexion products.AstraZeneca | Results Presentation Deck | 41 slides · AstraZeneca
Conference presentation Investor relations 1 hit
02
Includes a footer note regarding the update date of March 24th, 2023.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations 1 hit
03
The slide uses a numbered list to present five key pillars of the company's value proposition.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a hierarchical structure to connect a high-level objective to three specific strategic pillars.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
06
The slide uses a timeline format to communicate both past achievements and future R&D milestones.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
Uses a timeline-style vertical flow to represent the 'need' metrics.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Includes a quote from Keith Nuechterlein, Ph.D. regarding the clinical significance of the Symbol Coding results.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
The slide uses a vertical process flow to show the progression of clinical trials and data validation.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
12
The slide highlights that lower doses of RL-007 (40 or 80 mg TID) show statistically significant improvements compared to placebo in cognitive endpoints.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
13
The slide uses a standard clinical trial flow diagram to illustrate the study methodology.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
15
The slide uses a split-layout: left side defines the condition and market size, right side highlights the 'unaddressed need' (treatment gap, comorbidity, and lack of innovation).ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
16
The slide uses a split-layout with a left-hand summary table and a right-hand clinical data visualization.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
18
The slide uses topographical brain maps to visualize EEG data changes.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
19
The chart displays pharmacodynamic data from a clinical trial, specifically EEG beta power changes relative to pre-dose levels.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
20
The slide uses a checkmark matrix to highlight the competitive advantage of the drug candidate.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
22
The slide uses a dual-column layout: left side defines the disease and market size, right side outlines the clinical 'urgent need' using a vertical process/list flow.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
24
The slide uses a timeline-based process diagram to illustrate clinical trial protocols.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Beat · TractionLoop · Golden Circle1 hit
27
Uses a process-style timeline to list key statistics about the OUD crisis.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Loop · Golden Circle1 hit
28
Includes a line chart showing HCQN subscale reduction over time and a two-stage trial design diagram.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Loop · Golden Circle1 hit
29
The table highlights DMX-1002's unique profile compared to standard Medication Assisted Therapy and Withdrawal Support.ATAI | Investor Presentation Deck | 30 slides · atai
Pitch deck Investor relations Loop · Golden Circle1 hit
02
The slide uses stacked bar charts to compare AUM vs Base Fees for four different business segmentations.BlackRock | Results Presentation Deck | 12 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
03
Includes LTM organic asset growth rate and LTM organic base fee growth rate metrics.BlackRock | Results Presentation Deck | 12 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit